328 related articles for article (PubMed ID: 32558942)
1. Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma.
Leung MS; Chan KK; Dai WJ; Wong CY; Au KY; Wong PY; Wong CC; Lee TK; Ng IO; Kao WJ; Lo RC
J Pathol; 2020 Sep; 252(1):65-76. PubMed ID: 32558942
[TBL] [Abstract][Full Text] [Related]
2. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
3. Ventilagolin Suppresses Migration, Invasion and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells by Downregulating Pim-1.
Liu Y; Cheng DH; Lai KD; Su H; Lu GS; Wang L; Lv JH
Drug Des Devel Ther; 2021; 15():4885-4899. PubMed ID: 34880599
[TBL] [Abstract][Full Text] [Related]
4. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
[TBL] [Abstract][Full Text] [Related]
5. Biochemical changes of salivary gland adenoid cystic carcinoma cells induced by SGI-1776.
Hou X; Yu Y; Feng J; Wang J; Zheng C; Ling Z; Ge M; Zhu X
Exp Cell Res; 2017 Mar; 352(2):403-411. PubMed ID: 28228352
[TBL] [Abstract][Full Text] [Related]
6. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
7. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
[TBL] [Abstract][Full Text] [Related]
8. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST
Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557
[TBL] [Abstract][Full Text] [Related]
9. Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma.
Weirauch U; Beckmann N; Thomas M; Grünweller A; Huber K; Bracher F; Hartmann RK; Aigner A
Neoplasia; 2013 Jul; 15(7):783-94. PubMed ID: 23814490
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of Rab17 promotes tumourigenic properties of hepatocellular carcinoma cells via Erk pathway.
Qi J; Zhao P; Li F; Guo Y; Cui H; Liu A; Mao H; Zhao Y; Zhang X
Int J Clin Exp Pathol; 2015; 8(5):4963-71. PubMed ID: 26191189
[TBL] [Abstract][Full Text] [Related]
11. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
Yang Q; Chen LS; Gandhi V
Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
[TBL] [Abstract][Full Text] [Related]
13. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
14. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
Chen LS; Redkar S; Bearss D; Wierda WG; Gandhi V
Blood; 2009 Nov; 114(19):4150-7. PubMed ID: 19734450
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
16. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
17. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
18. (-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma.
Pei T; Meng Q; Han J; Sun H; Li L; Song R; Sun B; Pan S; Liang D; Liu L
Oncotarget; 2016 Jul; 7(28):43475-43491. PubMed ID: 27259268
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.
Mumenthaler SM; Ng PY; Hodge A; Bearss D; Berk G; Kanekal S; Redkar S; Taverna P; Agus DB; Jain A
Mol Cancer Ther; 2009 Oct; 8(10):2882-93. PubMed ID: 19825806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]